Does allogeneic stem cell transplant treat myelofibrosis?

Transplantation supplies healthy donor stem cells that can take over blood-cell production from the affected marrow. Donor immune cells may also act against the abnormal cells driving myelofibrosis. The treatment is intensive, so a specialist transplant team assesses each person's disease and fitness before recommending it.

Myelofibrosis causes scarring in the bone marrow and can disrupt normal production of red cells, white cells and platelets. Blood formation may shift to organs such as the spleen, which can become enlarged. Transplant assessment considers blood counts, symptoms, marrow findings, changes in abnormal cells, spleen-related problems, prior treatment and the expected course of the condition.

Before the donor-cell infusion, conditioning treatment suppresses the recipient's marrow and immune system. The plan may be adjusted to the person's general health and organ function. Following infusion, the care team monitors for donor-cell engraftment, infection, graft-versus-host disease and changes in blood counts or spleen symptoms.

Record fatigue, night sweats, appetite changes, abdominal fullness and how symptoms affect daily activities. Take this record, your medicine list, transfusion history and previous marrow reports to the appointment. The team may request tissue typing, heart and lung checks, infection tests and other assessments to judge whether transplantation is feasible.

Ask for a clear comparison between transplantation and continuing non-transplant treatment in your situation. Explore donor-search plans, fertility preservation, caregiver arrangements, time near the transplant centre and precautions during immune recovery. Keep taking prescribed myelofibrosis medicines unless the haematology team gives a specific changeover plan.

Contact your treating team promptly for fever, chills, worsening shortness of breath, new bleeding, marked dizziness, severe abdominal pain, a quickly enlarging or painful abdomen, persistent vomiting or diarrhoea, or a new extensive rash. During transplant care, use the exact temperature and contact guidance supplied by your centre.

Request emergency assistance for collapse, heavy bleeding, severe difficulty breathing, sudden confusion or loss of consciousness. Tell emergency clinicians that you have myelofibrosis and whether you are receiving transplant conditioning or immune-suppressing medicines, as this affects immediate assessment.

Consider asking which myelofibrosis findings make transplant suitable now, how spleen size or current medicines affect the plan, what type of donor match is available, which conditioning treatment is proposed and how recovery will be monitored. Ask whom to call if symptoms change before admission.